AZD9412: Development discontinued

Synairgen said AstraZeneca discontinued development and returned rights to AZD9412. The biotech said the double-blind, placebo-controlled, international Phase IIa INEXAS trial evaluating inhaled AZD9412 to treat respiratory virus-induced exacerbations of asthma did not meet AZ's predefined progression criteria.

In 2016, AZ discontinued the INEXAS trial after an interim analysis showed that an “overall very low number of reported severe exacerbations could make primary endpoint conclusions difficult” (see BioCentury, Oct. 24, 2016)...